Terms: = Lymphoma AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
12 results:
1. Poricoic acid A (PAA) inhibits T-cell acute lymphoblastic leukemia through inducing autophagic cell death and ferroptosis.
Chen L; Fang W; Liu J; Qi X; Zhao L; Wang Y; Liu Y; Kong D; Sun X; Li X; Sha Q; Sun G
Biochem Biophys Res Commun; 2022 Jun; 608():108-115. PubMed ID: 35397422
[TBL] [Abstract] [Full Text] [Related]
2. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
[TBL] [Abstract] [Full Text] [Related]
3. Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell lymphoma.
Lone W; Bouska A; Sharma S; Amador C; Saumyaranjan M; Herek TA; Heavican TB; Yu J; Lim ST; Ong CK; Slack GW; Savage KJ; Rosenwald A; Ott G; Cook JR; Feldman AL; Rimsza LM; McKeithan TW; Greiner TC; Weisenburger DD; Melle F; Motta G; Pileri S; Vose JM; Chan WC; Iqbal J
Clin Cancer Res; 2021 Nov; 27(21):6039-6053. PubMed ID: 34426436
[TBL] [Abstract] [Full Text] [Related]
4. Aggressive B-cell lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract] [Full Text] [Related]
5. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
6. High mtor expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.
Khanna A; Bhushan B; Chauhan PS; Saxena S; Gupta DK; Siraj F
Clin Exp Med; 2018 May; 18(2):221-227. PubMed ID: 29076004
[TBL] [Abstract] [Full Text] [Related]
7. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract] [Full Text] [Related]
8. IL-15 activates mtor and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Blood; 2016 Sep; 128(11):1475-89. PubMed ID: 27465917
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract] [Full Text] [Related]
10. Histone deacetylase inhibitor potentiated the ability of mtor inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
[TBL] [Abstract] [Full Text] [Related]
11. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
[TBL] [Abstract] [Full Text] [Related]
12. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Burczynski ME; Twine NC; Dukart G; Marshall B; Hidalgo M; Stadler WM; Logan T; Dutcher J; Hudes G; Trepicchio WL; Strahs A; Immermann F; Slonim DK; Dorner AJ
Clin Cancer Res; 2005 Feb; 11(3):1181-9. PubMed ID: 15709187
[TBL] [Abstract] [Full Text] [Related]
